The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer - results from a phase 1 study https://www.medrxiv.org/content/10.1101/2023.02.15.23285939